The weight-loss drug revolution just took an unexpected turn. Scripps Research is launching a nationwide trial to test whether Zepbound's active ingredient, tirzepatide, can treat long Covid by targeting the chronic inflammation plaguing millions of patients. With 20 million Americans affected and limited treatment options, researchers are betting on GLP-1 drugs' powerful anti-inflammatory properties to provide relief where traditional medicine has fallen short.
The obesity wonder drug Zepbound is about to get its biggest test yet - not for weight loss, but as a potential breakthrough treatment for long Covid. Scripps Research Translational Institute just launched a nationwide trial recruiting 1,000 patients to test whether tirzepatide, the drug's active ingredient, can tackle the chronic inflammation that defines long Covid.
The timing couldn't be more critical. As many as 20 million Americans are living with long Covid symptoms that can last months or years after their initial infection. Despite the Biden administration's $1.8 billion research investment, effective treatments remain elusive.
"The rationale for a GLP-1 drug is its powerful body-wide and brain anti-inflammatory properties," Eric Topol, director of the Scripps institute sponsoring the trial, tells researchers. It's a bold pivot from the drug's obesity roots, but mounting evidence suggests GLP-1 medications have broad anti-inflammatory effects that go far beyond appetite suppression.
The breakthrough moment came when doctors noticed something unexpected in their practices. David Kaufman, who runs the Center for Complex Diseases in Seattle and Mountain View, started seeing long Covid patients report less fatigue after taking GLP-1s for weight loss. "What it does is it seems to move the needle so patients can become more functional," Kaufman told WIRED.
That anecdotal evidence is now getting the full clinical trial treatment. But this isn't your typical medical study. The Scripps trial is completely remote - participants receive medication by mail and track symptoms using fitness trackers and smart scales from home. For a patient population where many are housebound or bedbound, the design is revolutionary.
"If you're requiring people to come into a clinic, you're systematically excluding the most severely affected folks," explains Julia Moore Vogel, the trial's co-principal investigator who has long Covid herself. Traditional in-person trials have struggled with recruitment precisely because travel is often impossible for the sickest patients.
The science behind using tirzepatide for long Covid centers on inflammation. Researchers have found persistent inflammatory markers in many long Covid patients, likely caused by lingering viral particles or autoantibodies attacking the body's own tissues. The drug's proven anti-inflammatory effects could theoretically calm this chronic immune system overdrive.
Early results from off-label use look promising. Kaufman presented data at a recent long Covid workshop showing that over 350 patients treated with microdoses of tirzepatide experienced 60-90% decreases in fatigue, brain fog, pain, and inflammatory symptoms. He's currently treating 40-50 long Covid patients with tiny doses - one-tenth the standard 2.5 milligram starting dose.
The pharmaceutical industry's limited investment in long Covid research makes the Scripps trial particularly significant. While companies have poured billions into GLP-1 development for obesity and diabetes, chronic post-viral conditions haven't attracted the same level of commercial interest. The Patient-Led Research Collaborative, a long Covid advocacy group, calls trials like this "urgently needed."
But researchers are tempering expectations. Long Covid presents with over 200 documented symptoms ranging from cognitive issues to cardiovascular problems to severe fatigue. "There's unlikely to be a one-size-fits-all treatment," the Scripps team acknowledges. Even successful results might represent just one piece of a complex treatment puzzle.
The trial's remote design also signals a shift in how clinical research approaches chronic conditions. By eliminating travel barriers, researchers can access patients who've been systematically excluded from traditional studies. It's a model that could reshape how we test treatments for other debilitating conditions.
Results won't be available for over a year, but the trial represents the most ambitious attempt yet to repurpose obesity medications for long Covid. An NIH-sponsored trial is also planning to test GLP-1 drugs for the condition, suggesting growing scientific confidence in the approach.
The Scripps trial represents more than just another drug study - it's a fundamental shift in how we approach both long Covid treatment and clinical research design. By making trials accessible to the sickest patients and repurposing proven medications for new uses, researchers are opening pathways that could benefit millions. Whether tirzepatide becomes a long Covid game-changer remains to be seen, but the innovative approach to testing it might be just as important as the results themselves.
